New Frontiers in Metastatic Melanoma: A Closer
Look at the Role of Immunotherapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 25, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Merck & Company

Description:
Melanoma is the most serious type of skin cancer and prognosis is usually good for patients, but when the melanoma recurs after initial surgery, prognosis is especially poor. Fortunately for patients with unresectable, recurrent melanoma, and the physicians that treat them, significant progress has been made in the treatment of this deadly disease over the past few years. In unresectable melanoma that is recurrent, the goal of treatment is to shrink or get rid of the melanoma and prevent the disease from spreading. Recently, new classes of immunotherapies have become available for patients with unresectable melanoma. These therapies help the immune system sustain an active response in its attack on melanoma cells.

Upon Completion of this activity, participants will be able to:

  • Analyze the role of new immunotherapeutic combination therapies in the management of patients with metastatic melanoma

  • Explore individualized immunotherapeutic treatment regimens for patients with metastatic melanoma based on tumor characteristics and patient factors

  • Identify key economic challenges surrounding metastatic melanoma and the potential cost-effectiveness of immunotherapies

  • Discuss best practices for the management of the unique toxicity profiles associated with immunotherapy
     

Faculty: Philip Friedlander, MD
The Empire State Building
Assistant Professor of Medicine
Hematology and Oncology
Ichan School of Medicine

Disclosure:

Dr. Friedlander serves on advisory boards for EMD Serono, Merck and Novartis. He also holds stock in Allergan, Cloud Security Corp, Incyte and Merrimack. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by an educational grant from
Merck & Company

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue